BIOPHARMA STOCK NEWS FLASH
APLS provides SYFOVRE safety update
Background:
SYFOVRE approved by FDA
• Feb 2023
• pegcetacoplan injection
• for GA 2nd to AMD
July 17, 2023
News breaks re: safety concerns
Stock down >50%
Today’s Safety Update
• 7 confirmed retinal vasculitis since launch
⇨ 4 occlusive
⇨ 3 non-occlusive
⇨ +1 unconfirmed
2 in April
2 in May
3 in June
• 68,000 commercials vials distributed
• Updated analysis
⇨ No mfg issues
⇨ No quality issues
⇨ No contaminants
• 23,000 clin trial injections
⇨ Deeper scrub of data
⇨ No vasculitis
More ahead for APLS this weekend/week
7/31 Q2 update
#ASRS2023 presentations
APLS @ #ASRS23 7/28-8/1
• 7 presentation in coming days at #ASRS23
⇨ Tomorrow - 30 month safety & efficacy
ASRS Safety committee (ReST)
Reported safety update today*
• ReST Committee working with APLS
• Similar info reported today as APLS update
• But some info on …
⇨ Panuveitis & Infectious endophthalmitis
⇨ Positive Committee comments re: APLS interactions
Prior report on Internet...
Undisclosed conflict on ReST committee*
*From info on Internet not confirmed by BPIQ
EcoR1 loads up on APLS
after recent stock drop
APLS is a hedge fund favorite
• 10/36 top biopharma funds
⇨ end Q1 filings
• 1 of most widely held smid-caps
Wall Street analysts re: APLS safety issue ...
• Speculate solvable
⇨ Not MOA
⇨ See images
Back to biopharma hedge funds
Since safety issues surfaced ...
From SEC filings ...
No reported selling
In fact...
7/18/23
EcoR1 bought more APLS
• 855,900 shares
• Now owns 6,307,547
In a few weeks ...
• Hedge fund Q2 13F filings
• Value of APLS holdings prob <1/2 Q1
⇨ because stock price drop
⇨ Not because HFs selling
⇨ HFs holding APLS
Article History:
Originally posted 7/31/23 (RB)
This is not investment, legal or tax advice. Do your own diligence and seek the advice of professionals.